Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle

Human Molecular Genetics

Volumn 18, Issue 17, 2009, Pages 3194-3205

  Kramerova, Irina ^a   Kudryashova, Elena ^a   Wu, Benjamin ^a   Germain, Sean ^b   Vandenborne, Krista ^b   Romain, Nadine ^c   Haller, Ronald G ^c,d,e   Verity, M Anthony ^a   Spencer, Melissa J ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Institute for Exercise and Environmental Medicine Dallas   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALPAIN 3; MANGANESE SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALPAIN 3 DEFICIENCY; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; ENZYME SYNTHESIS; FATTY ACID OXIDATION; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; OXIDATIVE STRESS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SKELETAL MUSCLE;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ADENOSINE TRIPHOSPHATE; ANIMALS; CALPAIN; ENERGY METABOLISM; FATTY ACIDS; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MUSCLE PROTEINS; MUSCLE, SKELETAL; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 68749103451     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp257     Document Type: Article

References (53)

1. Goll, D.E., Thompson, V.F., Li, H., Wei, W. and Cong, J. (2003) The calpain system. Physiol. Rev., 83, 731-801.
2. Suzuki, K., Hata, S., Kawabata, Y. and Sorimachi, H. (2004) Structure, activation, and biology of calpain. Diabetes, 53 (Suppl. 1 , S12-S18.
3. Richard, I., Broux, O., Allamand, V., Fougerousse, F., Chiannilkulchai, N., Bourg, N., Brenguier, L., Devaud, C., Pasturaud, P., Roudaut, C. et al. (1995) Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell, 81, 27-40.
4. Groen, E.J., Charlton, R., Barresi, R., Anderson, L.V., Eagle, M., Hudson, J., Koref, M.S., Straub, V. and Bushby, K.M. (2007) Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain, 130, 3237-3249.
5. Kramerova, I., Beckmann, J.S. and Spencer, M.J. (2007) Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochim. Biophys. Acta, 1772, 128-144.
6. Laval, S.H. and Bushby, K.M. (2004) Limb-girdle muscular dystrophies - from genetics to molecular pathology. Neuropathol. Appl. Neurobiol. 30, 91-105.
7. Milic, A., Daniele, N., Lochmuller, H., Mora, M., Comi, G.P., Moggio, M., Noulet, F., Walter, M.C., Morandi, L., Poupiot, J. et al. (2007) A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul. Disord., 17, 148-156.
8. Fanin, M., Nascimbeni, A.C., Fulizio, L. and Angelini, C. (2005) The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul. Disord., 15, 218-224.
9. Saenz, A., Leturcq, F., Cobo, A.M., Poza, J.J., Ferrer, X., Otaegui, D., Camano, P., Urtasun, M., Vilchez, J., Gutierrez-Rivas, E. et al. (2005) LGMD2A: Genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain, 128, 732-742.
10. Fardeau, M., Eymard, B., Mignard, C., Tomé, F.M., Richard, I. and Beckmann, J.S. (1996) Chromosome 15-linked limb-girdle muscular dystrophy: Clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul. Disord., 6, 447-453.
11. Urtasun, M., Saenz, A., Roudaut, C., Poza, J.J., Urtizberea, J.A., Cobo, A.M., Richard, I., Garcia Bragado, F., Leturcq, F., Kaplan, J.C. et al. (1998) Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain, 121, 1735-1747.
12. Kawai, H., Akaike, M., Kunishige, M., Inui, T., Adachi, K., Kimura, C., Kawajiri, M., Nishida, Y., Endo, I., Kashiwagi, S. et al. (1998) Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. Muscle Nerve, 21, 1493-1501.
13. Chae, J., Minami, N., Jin, Y., Nakagawa, M., Murayama, K., Igarashi, F. and Nonaka, I. (2001) Calpain 3 gene mutations: Genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul. Disord., 11, 547-555.
14. Hermanova, M., Zapletalova, E., Sedlackova, J., Chrobakova, T., Letocha, O., Kroupova, I., Zamecnik, J., Vondracek, P., Mazanec, R., Marikova, T. et al. (2006) Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. Muscle Nerve, 33, 424-432.
15. Kramerova, I., Kudryashova, E., Tidball, J.G. and Spencer, M.J. (2004) Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum. Mol. Genet., 13, 1373-1388.
16. Richard, I., Roudaut, C., Marchand, S., Baghdiguian, S., Herasse, M., Stockholm, D., Ono, Y., Suel, L., Bourg, N., Sorimachi, H. et al. (2000) Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IKBa/nuclear factor KB pathway perturbation in mice. J. Cell Biol., 151, 1-9.
17. Spencer, M.J., Guyon, J.R., Sorimachi, H., Potts, A., Richard, I., Herasse, M., Chamberlain, J., Dalkilic, I., Kunkel, L.M. and Beckmann, J.S. (2002) Stable expression of calpain 3 from a muscle transgene in vivo: Immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc. Natl Acad. Sci. USA, 99, 8874-8879.
18. Kramerova, I., Kudryashova, E., Venkatraman, G. and Spencer, M.J. (2005) Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum. Mol. Genet., 14, 2125-2134.
19. Kramerova, I., Kudryashova, E., Wu, B. and Spencer, M.J. (2006) Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation. Mol. Cell. Biol., 26, 8437-8447.
20. Taveau, M., Bourg, N., Sillon, G., Roudaut, C., Bartoli, M. and Richard, I. (2003) Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol. Cell. Biol., 23, 9127-9135.
21. Baghdiguian, S., Martin, M., Richard, I., Pons, F., Astier, C., Bourg, N., Hay, R.T., Chemaly, R., Halaby, G., Loiselet, J. et al. (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med., 5, 503-511 [Published erratum appeared in Nat. Med., 5, 849 (1999)].
22. Benayoun, B., Baghdiguian, S., Lajmanovich, A., Bartoli, M., Daniele, N., Gicquel, E., Bourg, N., Raynaud, F., Pasquier, M.A., Suel, L. et al. (2008) NF-kappaB-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J., 22, 1521-1529.
23. Kramerova, I., Kudryashova, E., Wu, B., Ottenheijm, C., Granzier, H. and Spencer, M.J. (2008) Novel role of calpain-3 in the triad-associated protein complex regulating calcium release in skeletal muscle. Hum. Mol. Genet., 17, 3271-3280.
24. Sorimachi, H., Kinbara, K., Kimura, S., Takahashi, M., Ishiura, S., Sasagawa, N., Sorimachi, N., Shimada, H., Tagawa, K., Maruyama, K. et al. (1995) Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J. Biol. Chem., 270, 31158-31162.
25. Kinbara, K., Sorimachi, H., Ishiura, S. and Suzuki, K. (1997) Muscle-specific calpain, p94, interacts with the extreme C-terminal region of connectin, a unique region flanked by two immunoglobulin C2 motifs. Arch. Biochem. Biophys., 342, 99-107.
26. Huang, Y., de Morree, A., van Remoortere, A., Bushby, K., Frants, R.R., Dunnen, J.T. and van der Maarel, S.M. (2008) Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum. Mol. Genet. 17, 1855-1866.
27. Cohen, N., Kudryashova, E., Kramerova, I., Anderson, L.V., Beckmann, J.S., Bushby, K. and Spencer, M.J. (2006) Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice. Proteomics, 6, 6075-6084.
28. DiMauro, S. and Schon, E.A. (2003) Mitochondrial respiratory-chain diseases. N. Engl. J. Med., 348, 2656-2668.
29. Garcia, M., Bondada, V. and Geddes, J.W. (2005) Mitochondrial localization of mu-calpain. Biochem. Biophys. Res. Commun., 338 1241-1247.
30. Mason, K.E., Stofan, D.A. and Szweda, L.I. (2005) Inhibition of very long chain acyl-CoA dehydrogenase during cardiac ischemia. Arch. Biochem. Biophys., 437, 138-143.
31. Lubos, E., Handy, D.E. and Loscalzo, J. (2008) Role of oxidative stress and nitric oxide in atherothrombosis. Front. Biosci., 13, 5323-5344.
32. Zeevalk, G.D., Bernard, L.P., Song, C., Gluck, M. and Ehrhart, J. (2005) Mitochondrial inhibition and oxidative stress: Reciprocating players in neurodegeneration. Antioxid. Redox Signal., 7, 1117-1139.
33. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
34. Ungvari, Z., Buffenstein, R., Austad, S.N., Podlutsky, A., Kaley, G. and Csiszar, A. (2008) Oxidative stress in vascular senescence: Lessons from successfully aging species. Front. Biosci., 13, 5056-5070.
35. Pénisson-Besnier, I., Richard, I., Dubas, F., Beckmann, J.S. and Fardeau, M. (1998) Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. Muscle Nerve, 21, 1078-1080.
36. Irwin, W.A., Bergamin, N., Sabatelli, P., Reggiani, C., Megighian, A., Merlini, L., Braghetta, P., Columbaro, M., Volpin, D., Bressan, G.M. et al. (2003) Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet., 35, 367-371.
37. Kuznetsov, A.V., Winkler, K., Wiedemann, F.R., von Bossanyi, P., Dietzmann, K. and Kunz, W.S. (1998) Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol. Cell. Biochem., 183, 87-96.
38. Millay, D.P., Sargent, M.A., Osinska, H., Baines, C.P., Barton, E.R., Vuagniaux, G., Sweeney, H.L., Robbins, J. and Molkentin, J.D. (2008) Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat. Med., 14, 442-447.
39. Deconinck, N. and Dan, B. (2007) Pathophysiology of Duchenne muscular dystrophy: Current hypotheses. Pediatr. Neurol., 36, 1-7.
40. Wang, H., Lim, P.J., Karbowski, M. and Monteiro, M.J. (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet., 18, 737-752.
41. Lin, M.T. and Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787-795.
42. Angelin, A., Tiepolo, T., Sabatelli, P., Grumati, P., Bergamin, N., Golfieri, C., Mattioli, E., Gualandi, F., Ferlini, A., Merlini, L. et al. (2007) Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc. Natl Acad. Sci. USA, 104, 991-996.
43. Rasola, A. and Bernardi, P. (2007) The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis, 12, 815-833.
44. Merlini, L., Angelin, A., Tiepolo, T., Braghetta, P., Sabatelli, P., Zamparelli, A., Ferlini, A., Maraldi, N.M., Bonaldo, P. and Bernardi, P. (2008) Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc. Natl Acad. Sci. USA, 105, 5225-5229.
45. Hansson, M.J., Mattiasson, G., Mansson, R., Karlsson, J., Keep, M.F., Waldmeier, P., Ruegg, U.T., Dumont, J.M., Besseghir, K. and Elmer, E. (2004) The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr., 36, 407-413.
46. Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S., Osinska, H., Hambleton, M.A., Brunskill, E.W., Sayen, M.R., Gottlieb, R.A., Dorn, G.W. et al. (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 434, 658-662.
47. Reutenauer, J., Dorchies, O.M., Patthey-Vuadens, O., Vuagniaux, G. and Ruegg, U.T. (2008) Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br. J. Pharmacol., 155, 574-584.
48. Tidball, J.G., Albrecht, D.E., Lokensgard, B.E. and Spencer, M.J. (1995) Apoptosis precedes necrosis of dystrophin-deficient muscle. J. Cell Sci., 108, 2197-2204.
49. Verity, M.A. (1991) Infantile Pompe's disease, lipid storage, and partial carnitine deficiency. Muscle Nerve, 14, 435-440.
50. Liu, M., Walter, G.A., Pathare, N.C., Forster, R.E. and Vandenborne, K. (2007) A quantitative study of bioenergetics in skeletal muscle lacking carbonic anhydrase III using 31P magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA, 104, 371-376.
51. Pathare, N., Vandenborne, K., Liu, M., Stevens, J.E., Li, Y., Frimel, T.N. and Walter, G.A. (2008) Alterations in inorganic phosphate in mouse hindlimb muscles during limb disuse. NMR Biomed., 21, 101-110.
52. Elliott, M.A., Walter, G.A., Swift, A., Vandenborne, K., Schotland, J.C. and Leigh, J.S. (1999) Spectral quantitation by principal component analysis using complex singular value decomposition. Magn. Reson. Med., 41, 450-455.
53. Lehman, T.C., Hale, D.E., Bhala, A. and Thorpe, C. (1990) An acyl-coenzyme A dehydrogenase assay utilizing the ferricenium ion. Anal. Biochem., 186, 280-284.